Split Cyclin-Dependent Kinase 4/6–Retinoblastoma 1 Axis in Pancreatic Cancer
Drugs targeting the cyclin-dependent kinase 4/6 (CDK4/6)–retinoblastoma 1 (RB1) axis have shown efficacy against multiple solid cancers, but their therapeutic potential in pancreatic cancer remains poorly defined. A recent report proposed that a “tailored” combination of first-line and second-line C...
Main Authors: | Xing Huang, Gang Zhang |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-11-01
|
Series: | Frontiers in Cell and Developmental Biology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fcell.2020.602352/full |
Similar Items
-
The Emerging Role of Cyclin-Dependent Kinases (CDKs) in Pancreatic Ductal Adenocarcinoma
by: Balbina García-Reyes, et al.
Published: (2018-10-01) -
Therapeutic effect of palbociclib in chondrosarcoma: implication of cyclin-dependent kinase 4 as a potential target
by: Zhengxiao Ouyang, et al.
Published: (2019-02-01) -
Molecular evidence for increased antitumor activity of gemcitabine in combination with a cyclin-dependent kinase inhibitor, P276-00 in pancreatic cancers
by: Rathos Maggie J, et al.
Published: (2012-08-01) -
Breast Cancer Resistance to Cyclin-Dependent Kinases 4/6 Inhibitors: Intricacy of the Molecular Mechanisms
by: Bin Wang, et al.
Published: (2021-05-01) -
Cyclin-Dependent Kinase Inhibitors in Hematological Malignancies—Current Understanding, (Pre-)Clinical Application and Promising Approaches
by: Anna Richter, et al.
Published: (2021-05-01)